相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
John H. Strickler et al.
CLINICAL CANCER RESEARCH (2021)
Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
Yosuke Sato et al.
BMC CANCER (2021)
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Jiali Yu et al.
NATURE MEDICINE (2021)
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Roberta Zappasodi et al.
NATURE (2021)
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis
Kevin Roarty et al.
FRONTIERS IN ONCOLOGY (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective
Libin Guo et al.
FRONTIERS IN IMMUNOLOGY (2020)
Combination of Fruquintinib and Anti-PD-1 for the Treatment of Colorectal Cancer
Yuanyuan Wang et al.
JOURNAL OF IMMUNOLOGY (2020)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Lihu Gu et al.
BMC CANCER (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer
E. Fiegle et al.
NEOPLASIA (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Toxicities associated with checkpoint inhibitors-an overview
Laura Spiers et al.
RHEUMATOLOGY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Kongju Wu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Metastasis inhibition in breast cancer by targeting cancer cell extravasation
Marcia R. Cominetti et al.
BREAST CANCER-TARGETS AND THERAPY (2019)
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
Katherine E. Lewis et al.
ONCOIMMUNOLOGY (2018)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du et al.
CELL RESEARCH (2018)
Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance
Maryam Althobiti et al.
HISTOPATHOLOGY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Wantong Song et al.
NATURE COMMUNICATIONS (2018)
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Marka R. Crittenden et al.
SCIENTIFIC REPORTS (2018)
Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
Sang-Soo Kim et al.
ONCOIMMUNOLOGY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Chloe Grasselly et al.
FRONTIERS IN IMMUNOLOGY (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immunotherapy for metastatic breast cancer
Tomoharu Sugie
CHINESE CLINICAL ONCOLOGY (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Regulatory T Cells: Differentiation and Function
George Plitas et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Balazs Gyoerffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer
Hiroyuki Suzuki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
Kazuyoshi Takeda et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
Karsten A. Pilones et al.
CLINICAL CANCER RESEARCH (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Girieca Lorusso et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
Ergun Kocak et al.
CANCER RESEARCH (2006)
分享论文
